$CANF News

Can-Fite Highlights Pancreatic Cancer Drug Progress

Can-Fite BioPharma Announces Publication Of Peer-Reviewed Scientific Article On Findings From Study Evaluating Piclidenoson For Treatment Of Canine Osteoarthritis

D. Boral Capital Upgrades Can Fite Biopharma to Buy, Announces $7 Price Target

Can-Fite BioPharma Plans To Advance Pancreatic Cancer Program Into Phase 2b Study Evaluating Namodenoson In Combination With Immunotherapy In Patients With Advanced Pancreatic Cancer

HC Wainwright & Co. Maintains Buy on Can Fite Biopharma, Raises Price Target to $5

Can-Fite BioPharma Announces Its Phase 2a Trial Of Namodenoson In Advanced Pancreatic Cancer Participants Demonstrates Over 30% Of Patient Had Stable Disease Observed, Preliminary Evidence Of Clinical Activity, Favorable Safety And Tolerability Profile

Can-Fite Biopharma's Veterinary Partner Vetbiolix Completes Enrollment In Phase 2 Study Of Piclidenoson For Osteoarthritis In Dogs; Topline Data Are Expected In Q3 2026

Can‑Fite BioPharma Secures Israeli Patent Allowance For A3AR Agonists, Covering Namodenoson In Obesity And Fat‑Loss Use

Nasdaq Surges Over 1%; ISM Services PMI Tops Views

Can-Fite BioPharma Enters Definitive Agreement For The Immediate Exercise Of Certain Outstanding Warrants To Purchase Up To An Aggregate Of 795,869 ADSs, Having An Exercise Price Of $9.34 Per ADS, Issued By Can-Fite In July 2025, At A Reduced Exercise Price Of $5.00 Per ADS

Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study

Can-Fite Biopharma Shares Halted On Circuit Breaker To The Upside, Stock Now Up 94.60%

Can-Fite BioPharma shares are trading higher after the company announced that its Phase 2a study evaluating Namodenoson for advanced pancreatic ductal adenocarcinoma met its primary endpoint.

Market-Moving News for March 4th

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Can-Fite Biopharma's Phase 2a Open-label Study Of Namodenoson For Advanced Pancreatic Ductal Adenocarcinoma Met Its Primary Endpoint

Can-Fite BioPharma Announces Publication Of Peer-Reviewed Study In International Journal Of Obesity Demonstrating Anti-Obesity Effect Of Namodenoson

Can-Fite BioPharma Secures Canadian Patent Allowance For A3 Adenosine Receptor Ligand Targeting Fat Loss

Discover the top movers in Thursday's pre-market session.

Can-Fite BioPharma Announces Patient With Advanced Decompensated Liver Cirrhosis Underwent Liver Transplantation Following Treatment With Namodenoson